What is Waypoint Bio?
Waypoint Bio is at the forefront of developing novel therapeutics by leveraging a sophisticated platform that integrates artificial intelligence, computer vision, and spatial pooled screening. The company's core focus is on creating AI-designed drugs, with its lead program being an in vivo CAR T asset. This asset is paired with a proprietary next-generation lentiviral vector, and clinical entry in China is anticipated by late 2026. Based in New York, Waypoint Bio is strategically expanding its platform's reach into biologics and other therapeutic areas, signaling a commitment to broad innovation in the pharmaceutical landscape.
How much funding has Waypoint Bio raised?
Waypoint Bio has raised a total of $34.5M across 2 funding rounds:
Angel/Seed
$14.5M
Series A
$20M
Angel/Seed (2024): $14.5M with participation from Hummingbird Ventures, Fifty Years Industries, and Recode Health Ventures
Series A (2026): $20M led by Time BioVentures, General Catalyst, Hummingbird Ventures, Amplify Partners, Mitsui & Co Global Investment, and Lux Capital
Key Investors in Waypoint Bio
Time BioVentures
Time BioVentures is a full-spectrum healthcare and life sciences venture capital firm based in Southern California, financing innovative entrepreneurs developing transformative healthcare technologies aimed at enhancing patients' quality of life.
General Catalyst
General Catalyst operates as a venture capital firm focused on identifying and supporting transformational business opportunities across multiple sectors and stages, deploying capital strategically to back entrepreneurs and management teams pursuing ambitious visions that reshape their respective industries.
Hummingbird Ventures
Hummingbird VC is a global seed investment fund that focuses on investing in outlier founders at the earliest stages of their ventures, providing significant support throughout the lifecycle of the companies they back.
What's next for Waypoint Bio?
The substantial enterprise-level funding and recent strategic investment position Waypoint Bio for accelerated growth and the advancement of its pipeline. The company's focus on AI-driven drug discovery, coupled with its expansion into new therapeutic modalities, suggests a forward-looking strategy aimed at addressing unmet medical needs. With a clear path toward clinical entry in China and ongoing platform development, Waypoint Bio is poised to make significant contributions to the biotechnology sector. Future capital injections will likely support further research and development, clinical trials, and potential market expansion.
See full Waypoint Bio company page
